Concepedia

Huub Jan Kleijn

HJ

Statistics

Publications

12

Citations

726

H-Index

10

Active since

2011

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Certara (United States)

Alexion Pharmaceuticals (United States)

MSD (Netherlands)

The Hague Centre for Strategic Studies

Huub Jan Kleijn is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, clinical pharmacology, and pharmacy.

Publications per year

2011–2023

12

Publications

12

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Matthew Kennedy, Andrew W. Stamford, Xia Chen et al. · Science Translational Medicine · 2016 · 417 citations

, , +17

Population pharmacokinetic–pharmacodynamic analysis for sugammadex‐mediated reversal of rocuronium‐induced neuromuscular blockade

Huub Jan Kleijn, Daniel P. Zollinger, Michiel W. van den Heuvel et al. · British Journal of Clinical Pharmacology · 2011 · 56 citations · Full text

, , +17

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

David Muccino, Alyn H. Morice, Surinder S. Birring et al. · ERJ Open Research · 2020 · 53 citations · Full text

, , +13

Population PK Analyses of Ubrogepant (MK‐1602), a CGRP Receptor Antagonist: Enriching In‐Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling

Chi‐Chung Li, Marissa F. Dockendorf, Ken Kowalski et al. · The Journal of Clinical Pharmacology · 2017 · 43 citations

, , +17

Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis

Jonathan Monteleone, Xiang Gao, Huub Jan Kleijn et al. · Frontiers in Neurology · 2021 · 35 citations · Full text

, , +17

1–5 of 12